Last updated: 2026-09-06 14:50:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Viridian Therapeutics, Inc. (VRDN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $22.93, with a market capitalization of $2.60B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.18 to $34.29. This page covers its latest market performance, valuation, price trends and company information.
$2.60B | |
$22.62 | |
$39.00 | |
$9.47 | |
$22.96 | |
566.88K | |
1.89M | |
-- | |
$34.29 | |
$13.18 | |
-- | |
-- |
Viridian Therapeutics, Inc. (VRDN) last closed at $22.96 as of 2026-09-04 23:31:00, unchanged from the previous close of $22.96.
During the latest regular trading session, VRDN traded between $9.47 and $39.00, with a volume of 566.88K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Viridian Therapeutics, Inc. (VRDN) moved from $23.88 to $22.93, representing a decline of 4.00% ($0.95).
The stock traded between $22.39 and $24.47 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.01 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 46.2%
VRDN is currently trading at $22.93, placing it 46.2% of the way from its 52-week low of $13.18 to its 52-week high of $34.29. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 252 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Viridian Therapeutics, Inc. (VRDN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.